Key Highlights

  • Quarterly Revenue reached $3.44 billion, climbing 12% year over year on a reported basis.
  • GAAP profit landed at $654 million, which is $2.56 a diluted share, while the year-earlier figure was $1.1 billion, or $4.20 a share.
  • Excluding special items, diluted EPS was $4.76, nearly matching the $4.80 posted in Q3 2025.
  • The 2026 revenue forecast was raised, now sitting at $13.15 billion through $13.25 billion, up from the earlier $13.1 billion through $13.2 billion range.
  • CASGEVY contributed $99 million and JOURNAVX added $58 million during the period.

Top-Line Gain of 12% Traces Back to Cystic Fibrosis Products and Recent Introductions

Vertex Pharmaceuticals (NASDAQ:VRTX) issued its release on Nov 2, 2026, covering the period ending Sep 30, 2026. Total sales were $3.44 billion, compared with $3.08 billion before, a 12% lift. U.S. receipts grew 10%, reaching $2.17 billion, and receipts from outside the U.S. climbed 16% to $1.27 billion, aided by currency tailwinds.

Management pointed mainly to cystic fibrosis medicines, helped by fresh ALYFTREK patient starts and firmer net realized prices. CASGEVY, JOURNAVX and PALSONIFY added to the total. Reimbursement for ALYFTREK now reaches 32 countries following seven new additions this quarter.

Reported Profit Drops Close to 40% on Crinetics-Linked Charges, With Adjusted Figures Level

Reported profit fell by roughly 39.6% on a calculated basis, landing at $654 million against a prior $1.1 billion. The company traced the decline to expenses tied to Crinetics Pharmaceuticals, a purchase completed Sep 1, 2026, including nearly $500 million for compensation and deal costs.

Operating spend across R&D (including in-process acquisitions) and SG&A totaled $2.2 billion, versus $1.5 billion earlier. Adjusted Net Income held at $1.2 billion in both periods as stronger product revenue was offset by heavier operating outlays, higher interest expense and lower interest income.

Liquidity in cash and marketable securities ended at $9.8 billion, down from $12.3 billion at year-end 2025. Net outflows of $9.0 billion for the Acquisition and Buybacks were partly covered by a $4.5 billion term loan. Management said close to 250,000 shares were bought back in the quarter for approximately $120 million.

Newer Products Including CASGEVY and JOURNAVX Diversify Vertex's Revenue Mix

CASGEVY posted $99 million in sales, rising 30% from the prior quarter and running at close to six-fold the $17 million of a year ago. In July the FDA cleared the product for young patients beginning at age two, covering sickle cell disease and a transfusion-dependent form of Beta thalassemia.

JOURNAVX delivered $58 million, up 18% from the previous quarter. Prescriptions filled surpassed 750,000, growing more than 40% sequentially. A patient savings program is set to continue into 2027 and wind down by mid-2027, after which management expects net pricing to stabilize. PALSONIFY generated $10 million during September, the first month it has been part of Vertex's portfolio.

Povetacicept Action Date of Nov 30 and a Shift in Finance Leadership Set the Road Ahead

For 2026, Vertex anticipates combined CASGEVY and JOURNAVX revenue of no less than $500 million, plus PALSONIFY revenue between $40 million and $50 million. Management now expects roughly $6.0 billion of combined non-GAAP R&D, in-process R&D and SG&A spending, lifted from a previous band of $5.65 billion through $5.75 billion. The non-GAAP tax rate outlook of 19.5% to 20.5% did not change.

Regulators have set Nov 30, 2026 as the decision date for povetacicept in IgA nephropathy, which would open a fifth commercial Business within kidney care. The current finance chief moves into a chief operating role, and the incoming CFO begins on Jan 1, 2027.